Φορτώνει......
ASCO 2016: highlights in breast cancer
At the 2016 ASCO Annual Meeting, several pertinent studies in the field of breast cancer were presented. MA17.R was the first randomized phase III trial to evaluate the prolongation of adjuvant aromatase-inhibitor (AI) therapy from 5 to 10 years; while a significant reduction of disease-free surviva...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Memo |
|---|---|
| Κύριοι συγγραφείς: | , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Springer Vienna
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5165027/ https://ncbi.nlm.nih.gov/pubmed/28058064 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12254-016-0300-6 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|